|
pubmed:abstractText |
The M5076 sarcoma was used to evaluate the antitumor activities of several analogs of Platinol presently undergoing clinical trials. The objective was to find a model yielding preclinical data which correlated with evolving clinical results, and thus potentially provide a validated model for the subsequent testing of new Platinol analogs. The model found to be useful consisted of mice implanted s.c. with M5076 tumor fragments. Platinol, carboplatin, and iproplatin were consistently active (T/C values greater than or equal to 125%), whereas spiroplatin was consistently inactive. These findings reflect the clinical activities of Platinol, carboplatin, and iproplatin and the essential clinical inactivity of spiroplatin thus far reported.
|
